These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 27180064)

  • 1. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
    Li Y; Donmez N; Sahinalp C; Xie N; Wang Y; Xue H; Mo F; Beltran H; Gleave M; Wang Y; Collins C; Dong X
    Eur Urol; 2017 Jan; 71(1):68-78. PubMed ID: 27180064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SRRM4 gene expression correlates with neuroendocrine prostate cancer.
    Li Y; Zhang Q; Lovnicki J; Chen R; Fazli L; Wang Y; Gleave M; Huang J; Dong X
    Prostate; 2019 Jan; 79(1):96-104. PubMed ID: 30155992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
    Li Y; Xie N; Chen R; Lee AR; Lovnicki J; Morrison EA; Fazli L; Zhang Q; Musselman CA; Wang Y; Huang J; Gleave ME; Collins C; Dong X
    Eur Urol; 2019 Aug; 76(2):157-166. PubMed ID: 30910347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
    Coleman DJ; Sampson DA; Sehrawat A; Kumaraswamy A; Sun D; Wang Y; Schwartzman J; Urrutia J; Lee AR; Coleman IM; Nelson PS; Dong X; Morrissey C; Corey E; Xia Z; Yates JA; Alumkal JJ
    Neoplasia; 2020 Jun; 22(6):253-262. PubMed ID: 32403054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
    Lee AR; Gan Y; Tang Y; Dong X
    EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.
    Lee AR; Gan Y; Xie N; Ramnarine VR; Lovnicki JM; Dong X
    Cancer Sci; 2019 Jan; 110(1):245-255. PubMed ID: 30417466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.
    Labrecque MP; Brown LG; Coleman IM; Lakely B; Brady NJ; Lee JK; Nguyen HM; Li D; Hanratty B; Haffner MC; Rickman DS; True LD; Lin DW; Lam HM; Alumkal JJ; Corey E; Nelson PS; Morrissey C
    Cancer Res; 2021 Sep; 81(18):4736-4750. PubMed ID: 34312180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.
    Lee AR; Li Y; Xie N; Gleave ME; Cox ME; Collins CC; Dong X
    Oncotarget; 2017 Apr; 8(17):27966-27975. PubMed ID: 28427194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer.
    Gan Y; Li Y; Long Z; Lee AR; Xie N; Lovnicki JM; Tang Y; Chen X; Huang J; Dong X
    EBioMedicine; 2018 May; 31():267-275. PubMed ID: 29759485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.
    Lee AR; Che N; Lovnicki JM; Dong X
    Front Oncol; 2018; 8():93. PubMed ID: 29666783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular events in neuroendocrine prostate cancer development.
    Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y
    Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
    Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
    Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4.
    Li Y; Chen R; Bowden M; Mo F; Lin YY; Gleave M; Collins C; Dong X
    Oncotarget; 2017 Sep; 8(40):66878-66888. PubMed ID: 28978002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
    Zhang X; Coleman IM; Brown LG; True LD; Kollath L; Lucas JM; Lam HM; Dumpit R; Corey E; Chéry L; Lakely B; Higano CS; Montgomery B; Roudier M; Lange PH; Nelson PS; Vessella RL; Morrissey C
    Clin Cancer Res; 2015 Oct; 21(20):4698-708. PubMed ID: 26071481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
    Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
    Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
    Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
    Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
    Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.